ASX:BGT Bio-Gene Technology (BGT) Stock Price, News & Analysis → #1 election stock (From Porter & Company) (Ad) Free BGT Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Bio-Gene Technology alerts: Email Address Ad Porter & Company#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. For the full story, click here. About Bio-Gene Technology Stock (ASX:BGT)Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. Its lead products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural oil extracted from a cultivar of eucalyptus cloeziana. The company has a research collaboration agreement with James Cook University to refine the process for oil extraction; and with BASF, Grains Research and Development Corporation, and Queensland Department of Agriculture and Fisheries for testing of Flavocide in grain storage. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.Read More Ad Porter & Company#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. For the full story, click here. BGT Stock News HeadlinesApril 15, 2024 | msn.comBio-Rad announces collaboration agreement with oncocyte to commercialize transplant monitoring with droplet digital PCRMarch 20, 2024 | msn.comBiotech with links to Boston sets record price for new gene therapy for rare childhood diseaseApril 30, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. March 4, 2024 | forbes.comScience Continues To Outpace Commercialization Of Cell And Gene TherapiesJanuary 23, 2024 | wsj.comBio-Gene Technology Ltd.December 13, 2023 | msn.com3 Biotechs With Promising Gene Therapies in the SpotlightDecember 11, 2023 | bizjournals.comUniversity of Pennsylvania Gene Therapy Program cuts staff by 25%, report saysDecember 4, 2023 | bizjournals.comDurham biotech seeks partner to advance its gene therapyApril 30, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. November 30, 2023 | msn.comGeneration bio cuts 40% of staff in blow for non-viral gene therapy sectorNovember 28, 2023 | markets.businessinsider.comGene Bio Medical (GBM): Leading the Charge in Biotechnological Innovation and Global Healthcare RevolutionNovember 8, 2023 | businesswire.combit.bio Unveils Cell Therapy Pipeline, Including Lead Candidate for Acute Liver Failure, and Significantly Expands Scientific Advisory Board with Global Experts in Cell TherapyNovember 8, 2023 | msn.comCell and gene therapy biotechs face access hurdles in EuropeNovember 6, 2023 | tmcnet.comGenevant Sciences to Collaborate with Novo Nordisk to Develop Gene Editing Treatment for Hemophilia ASeptember 25, 2023 | msn.comAre Gene Therapy Stocks The Market's Next Big Winners?September 20, 2023 | msn.comPelican and Primordial Genetics merge to form biotech company Primrose BioSeptember 18, 2023 | markets.businessinsider.comBiosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023August 28, 2023 | markets.businessinsider.comLife Science Firm Bio-Techne's Success Formula: Astute Acquisitions Offering TransformationAugust 15, 2023 | msn.comBTIG Maintains Mustang Bio (MBIO) Buy RecommendationAugust 11, 2023 | wsj.comSenior Personal Technology Columnist, The Wall Street JournalAugust 1, 2023 | bizjournals.comGene therapy startup founded by Pfizer, Biogen vet to shut downJune 5, 2023 | finance.yahoo.comForm Bio Announces FORMsightAI, a Breakthrough AI Solution Set for Predicting and Optimizing Cell & Gene Therapy ManufacturabilityMay 24, 2023 | bizjournals.comIn another mega-round, ElevateBio raises $401M for cell and gene therapyMay 19, 2023 | benzinga.comScout Bio to Present at Upcoming Gene and Cell Therapy SummitMay 10, 2023 | businesswire.comLife Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related DiseasesMay 4, 2023 | marketwatch.comMekonos Announces Research Collaboration With bit.bio to Advance Cell EngineeringMay 2, 2023 | marketwatch.comGene Engineered Subunit Vaccine Market Size 2023-2031 Industrial Regions by Absolute Reports | with [85 Pages]See More Headlines Receive BGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Gene Technology and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:BGT CUSIPN/A CIKN/A Webwww.bio-gene.com.au Phone61 3 9628 4178FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.75% Return on Assets-35.65% Debt Debt-to-Equity Ratio0.11 Current Ratio7.08 Quick Ratio6.72 Sales & Book Value Annual Sales$445,726.00 Price / Sales0.00 Cash FlowN/A Price / Cash Flow7.04 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares201,360,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.35 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Roger McPherson B.BusC.P.A., CPA, GAICD, Interim CFO & Company SecretaryMr. Peter Donald May AFA1MAFAIM, GAICD, M.B.A., MBA, Executive Director of Research & Development and Executive DirectorMr. Timothy Owen Grogan B.Sc.LLB, MD, CEO & DirectorKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersAlex DingSold 4,761,904 sharesTotal: $399,999.94 ($0.08/share)Richard JaggerSold 489,720 sharesTotal: $42,115.92 ($0.09/share) This page (ASX:BGT) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTruth about Trump you’ve never heardPorter & CompanyProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Gene Technology Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
